Blog Posts

Mon, Jun 1, 2026

Omada Health is riding the massive GLP-1 wave, but is it a buy? Discover key catalysts, financials, and hidden risks in our 2026 stock analysis.

Thu, May 28, 2026

A stock beat earnings but dropped 10%? Here's the 4-point framework I use to decide if a post-earnings crash is a setup or a trap — with $MRVL May 2026 as the live case study.

Wed, May 27, 2026

Up 100% on a stock and unsure when to sell? Here's the 4-question framework for deciding when to take profits — with real 2026 examples.

Thu, May 14, 2026

Is RBRK the next big growth stock? Dive into our May 2026 analysis on Rubrik's Microsoft partnership, ARR growth, and the $329M dilution risk.

Sun, May 10, 2026

TTD reported Q1 2026 earnings — revenue grew 12%, margins compressed. But the Q2 guide and $163M in buybacks tell a different story. Here's the breakdown.

Sat, Apr 4, 2026

The exact framework I use to screen 1700+ stocks for undervalued opportunities. Real metrics, real examples, no fluff.

Sat, Mar 28, 2026

Oil jumped from $70 to $100 on the Iran conflict. Here's how it kills rate cut hopes and which energy stocks I'm buying instead.

Sun, Mar 22, 2026

I tested 6 AI stock analysis tools. Most are ChatGPT wrappers. Here's what actually works for finding 10x stocks.

Fri, Mar 6, 2026

Forget consumer neobanks. I’m looking at the B2B infrastructure plays positioned for a 2026 rerating. Here is my data-driven shortlist.

Tue, Mar 3, 2026

I’m tracking three Aerospace & Defense stocks positioned for a rerating as the FY2026 budget hits the tape. Here is my data-driven plan.

Mon, Mar 2, 2026

My data-driven deep dive into the three nuclear energy stocks I'm watching for a 2026 breakout. No hype, just the numbers.

Tue, Feb 17, 2026

A look at my research process for finding asymmetric nuclear stocks before the March 2026 CERAWeek catalyst. No hype, just data.

Thu, Feb 5, 2026

I’m moving away from speculative biotech and focusing on these three oncology stocks with real revenue and upcoming 2026 catalysts.

Thu, Jan 15, 2026

Is UUUU a 10x opportunity or a trap? We analyze the US rare earth monopoly, 2026 catalysts, and critical risks before you invest.

Tue, Dec 23, 2025

Is ONON the next Lululemon? We analyze the 65% margins, the "LightSpray" catalyst, and the critical inventory red flag to watch in 2026.

Fri, Dec 19, 2025

A personal walk-through of how I’m researching clean energy stocks going into 2026… quietly.

Wed, Dec 17, 2025

Big Pharma faces a $200B revenue hole in 2026. Here are the 3 cash-rich, commercial-stage stocks I'm tracking to play the coming M&A wave.

Wed, Dec 17, 2025

Everyone is chasing AI hype. I’m looking at the 2026 regulatory deadline. Here are the 3 stocks positioned to profit from mandatory compliance.

Tue, Nov 25, 2025

The Artemis II launch is approaching. Here are the 3 commercial space stocks I'm analyzing for a potential 2026 breakout, focusing on data over hype.

Mon, Nov 17, 2025

Rocket Lab (RKLB) just crushed Q3 with 48% growth and a shock 37% Gross Margin. But the Neutron delay to 2026 has the market spooked. Here's my forensic audit of the numbers.

Thu, Jul 31, 2025

Explore NBIS stock's 10x potential in AI infrastructure. My honest take on its explosive growth, huge risks, and crucial catalysts for 2025. Is it a buy?